Medtronic Expands Neuromodulation Reach with Adaptive DBS Launch in India

Medtronic is global leader, announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve the quality of life of patients living with Parkinson's disease, which represents a meaningful advance over conventional DBS in how it responds to individual patient symptoms.  

aDBS is designed to automatically adjust therapy based on changes in brain signals or patient activity, and also offers an adaptive therapy that changes in response to a patient’s condition or medication needs to deliver more consistent symptom management for Parkinson’s disease. In real time, it also aims to provide more consistent symptom control, and minimizes side effects, and help to extend the life of the implanted device's battery. 

According to Towards Healthcare, the Neuromodulation Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 10.91 billion in 2026 to approximately USD 27.69 billion by 2035, representing a compound annual growth rate (CAGR) of 10.9% from 2026 to 2035. Growth is driven by the rising prevalence of neurological conditions of an aging population and escalating global rates of chronic pain, Parkinson's disease, epilesy and Alzheimer's, driving the need for nerve stimulation treatments. Technological advancements and rapid development of closed-loop stimulation algorithms with improved battery longevity and miniaturized implantable devices, which offer patients more precise and long-lasting relief when traditional medications fail. 

Senior Director, Neuroscience & Specialty Therapies, Medtronic India, Prateek Tiwari, said, "Our mission has always been to alleviate pain, restore health, and extend life, and the introduction of this system reflects our continued commitment to that mission. This milestone not only reaffirms our dedication to addressing the growing burden of Parkinson’s disease but also strengthens our leadership in bringing cutting-edge healthcare technologies to India to ultimately improve patients’ quality of life.’’ 

About Medtronic 

The company dominates due to its expansive product portfolio, heavy R&D investment, and decades of pioneering therapies for chronic pain, movement disorders, and epilepsy. It focuses on developing both implantable and non-implantable neurostimulation devices that interrupt pain signals or regulate brain and nerve activity. 

The system uses BrainSense technology, approved by the U.S. Food and Drug Administration, to adjust stimulation in real time based on brain signals and patient activity. 

Medtronic launches adaptive DBS for Parkinson’s 

Launch of Adaptive Deep Brain Stimulation (aDBS) system in India to provide real-time, personalized care for Parkinson's disease. India accounts for the burden of Parkinson's, making this technology highly significant for managing progressive neurological symptoms.  

Unlike conventional Deep Brain Stimulation (DBS), which delivers continuous, static electrical impulses to the brain, the aDBS system senses the patient's individual brain signals. 

A recent report by Towards Healthcare highlights that the Neuromodulation Market is witnessing growth due to mental health & depression for non-invasive transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS), which present growing market opportunities due to increasing awareness of treatment-resistant depression.